The evaluation of new drugs and therapeutic agents is a critical aspect of NIAID’s therapeutic research agenda. NIAID-sponsored therapeutics research has already had a dramatic impact on our understanding of the pathogenesis and clinical management of HIV infection over the last decade, and has helped define international guidelines for the treatment of primary HIV infection in adults and children and associated opportunistic infections and prophylactic regimens for these secondary infections, identify biological markers for predicting a drug's effectiveness and disease progression, and set the standard for use of antiretroviral drugs for preventing mother-to-infant transmission.
Within the NIAID, the DAIDS Therapeutics Research Program (TRP), which is divided into four branches: Drug Development and Clinical Sciences Branch, HIV Research Branch, Complications and Co-Infections Research Branch, and the Pediatric Medicine Branch, carries out the following therapeutic research activities:
For more information on NIAID’s therapeutic research efforts, visit the HIV/AIDS Therapeutics Research Area.
back to top
Last Updated October 29, 2007